1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Death knell sounds for CB1 antagonists

 
• By Alexandra Shimmings

Anti-obesity drugs that target the cannabinoid 1 receptor look set to be consigned to drug development history after the discontinuation of the two most advanced of these products in this class. [C#198601345:Sanofi-Aventis] is stopping all clinical trials of Acomplia (rimonabant) following its recent suspension in the EU because of psychiatric safety concerns, and [C#198600199:Pfizer]is discontinuing its Phase III candidate CP-945,598.

Anti-obesity drugs that target the cannabinoid 1 receptor look set to be consigned to drug development history after the discontinuation of the two most advanced of these products in this class. Sanofi-Aventis is stopping all clinical trials of Acomplia (rimonabant) following its recent suspension in the EU because of psychiatric safety concerns, and Pfizeris discontinuing its Phase III candidate CP-945,598.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Lilly Scores With Orforglipron In Diabetes, Generating Excitement For Obesity

 
• By Alaric DeArment

The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.

Ironwood To Consider All Options With Apraglutide Setback In SBS

 
• By Joseph Haas

With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

Compounding Unlikely To Solve GLP-1 Affordable Access Issues

 
• By Alaric DeArment

The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.

More from Therapy Areas

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

 
• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.

Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten

 
• By Alaric DeArment

BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.

Disappointing Asthma Phase II Results Take Wind Out Of Sanofi’s Amlitelimab

 
• By Andrew McConaghie

Sanofi’s OX40L candidate missed a Phase II primary endpoint, but the company believes it can still work in a sub-group of ‘heterogeneous inflammatory asthma’ patients.